Showing results (31-40 of 59) with videos related to
Sort By:
Pageof 6
Journal of Clinical Microbiology|March 3, 2007
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispeciesPierre Delobel, Marie-Thérèse Nugeyre, Michelle Cazabat, et al.The Journal of Antimicrobial Chemotherapy|June 25, 2013
Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequencePierre Delobel, Michelle Cazabat, Adrien Saliou, et al.Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2010
Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literatureGuillaume Martin-Blondel, Muriel Alvarez, Pierre Delobel, et al.AIDS (London, England)|March 21, 2009
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adultsFidéline Collin, Xavier Duval, Vincent Le Moing, et al.The Journal of Antimicrobial Chemotherapy|May 21, 2014
Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapyStéphanie Raymond, Adrien Saliou, Pierre Delobel, et al.The Journal of Antimicrobial Chemotherapy|July 23, 2013
Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencingStéphanie Raymond, Adrien Saliou, Florence Nicot, et al.Journal of Clinical Microbiology|December 11, 2012
Genotypic prediction of HIV-1 CRF01-AE tropismStéphanie Raymond, Pierre Delobel, Sylvie Rogez, et al.AIDS (London, England)|August 30, 2008
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropismStéphanie Raymond, Pierre Delobel, Maud Mavigner, et al.AIDS (London, England)|June 16, 2011
Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencingStéphanie Raymond, Adrien Saliou, Florence Nicot, et al.Plos One|October 31, 2009
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapyMaud Mavigner, Pierre Delobel, Michelle Cazabat, et al.Pageof 6